ABSTRACT
BACKGROUND: Peritoneal metastasis from biliary carcinoma (PMC) is associated with poor prognosis when treated with chemotherapy. OBJECTIVE: To evaluate the impact on survival of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and compare with conventional palliative chemotherapy for patients with PMC. MATERIAL AND METHODS: A prospective multicenter international database was retrospectively searched to identify all patients with PMC treated with a potentially curative CRS/HIPEC (CRS/HIPEC group). The overall survival (OS) was compared to patients with PMC treated with palliative chemotherapy (systemic chemotherapy group). Survival was analyzed using Kaplan-Meier method and compared with Log-Rank test. RESULTS: Between 1995 and 2015, 34 patients were included in the surgical group, and compared to 21 in the systemic chemotherapy group. In the surgical group, median peritoneal cancer index was 9 (range 3-26), macroscopically complete resection was obtained for 25 patients (73%). There was more gallbladder localization in the surgical group compared to the chemotherapy group (35% vs. 18%, p = 0.001). Median OS was 21.4 and 9.3 months for surgical and chemotherapy group, respectively (p=0.007). Three-year overall survival was 30% and 10% for surgical and chemotherapy group, respectively. CONCLUSION: Treatment with CRS and HIPEC for biliary carcinoma with peritoneal metastasis is feasible and may provide survival benefit when compared to palliative chemotherapy.
Subject(s)
Bile Duct Neoplasms/therapy , Cytoreduction Surgical Procedures/methods , Hyperthermia, Induced/methods , Peritoneal Neoplasms/therapy , Registries , Adult , Aged , Aged, 80 and over , Bile Duct Neoplasms/mortality , Bile Duct Neoplasms/secondary , Female , Follow-Up Studies , France/epidemiology , Humans , Male , Middle Aged , Peritoneal Neoplasms/mortality , Peritoneal Neoplasms/secondary , Prognosis , Prospective Studies , Survival Rate/trendsABSTRACT
BACKGROUND: The aim of this study was to investigate the potential of concentrated fluoride varnishes to reduce enamel loss from repeated cycles of citric acid erosion and toothbrush abrasion in vitro. METHODS: Polished human enamel samples were exposed to fluoride varnishes: Bifluorid10® (NaF&CaF2- 45,200 ppmF), Duraphat® (NaF 22,600 ppmF), Fluor-Protector® (difluorsilane 1000 ppmF) and a control coating of copal ether varnish (0 ppmF) group and a deionized water group. For each group of 16 samples, nine cycles of erosion and nine cycles of erosion-abrasion [1 cycle=erosion (0.3% citric acid, pH 3.2, 5 min)+artificial saliva (1 h, pH 7.0)+abrasion (120 linear strokes in artificial saliva from Oral B medium soft brushes 300 g loading]. The change in the enamel surface was evaluated using optical profilometry. RESULTS: Duraphat® and Bifluorid10® applications had a median (IQR) step height of 4.21 um (1.59) and 5.01 um (1.02). This was statistically significantly less than Fluor-Protector® 6.83 um (1.25), copal ether 7.22 um (1.97) and water 7.39 um (1.96) (p<0.001). For erosion-abrasion, both Duraphat® and Bifluorid® had statistically lower step heights than the other products (p<0.01). CONCLUSIONS: The action of fluoride in a range of single-application topical varnishes was effective in reducing enamel wear from erosion and erosion-abrasion in this laboratory study.
Subject(s)
Dental Enamel/drug effects , Fluorides, Topical/therapeutic use , Tooth Abrasion/prevention & control , Tooth Erosion/prevention & control , Calcium Fluoride/therapeutic use , Citric Acid/adverse effects , Dental Enamel/pathology , Drug Combinations , Fluorides/therapeutic use , Humans , Materials Testing , Phosphates/therapeutic use , Polyurethanes/therapeutic use , Resins, Plant , Saliva, Artificial/chemistry , Silanes/therapeutic use , Sodium Fluoride/therapeutic use , Toothbrushing/instrumentation , Water/chemistryABSTRACT
Oral health is dependent upon a thin mobile film of saliva on soft and hard tissues. Salivary proteins adhere to teeth to form the acquired enamel pellicle which is believed to protect teeth from acid erosion. This study investigated whether patients suffering diet-induced dental erosion had altered enamel pellicles. Thirty patients suffering erosion were compared to healthy age-matched controls. Subjects wore a maxillary splint holding hydroxyapatite and human enamel blocks for 1 h. The acquired enamel pellicle was removed from the blocks and compared to the natural incisor pellicle. Basic Erosive Wear Examination scores confirmed that dental erosion was present in erosion patients and absent from healthy age-matched controls. Erosion patients had half the amount of proteins (BCA assay) within the acquired pellicle forming on splint blocks compared to normal controls (p < 0.05). In particular, statherin, a calcium-binding protein, was 35% less abundant (p < 0.05). Calcium concentration within the acquired pellicle was also reduced by 50% in erosion patients (p < 0.001). In contrast, the natural pellicle on the incisor had similar amounts of total protein in erosion patients and healthy controls. In summary, the formation of new acquired pellicles on surfaces was reduced in erosion patients, which may explain their greater susceptibility to acid erosion of teeth.
Subject(s)
Dental Pellicle/chemistry , Tooth Erosion/metabolism , Adolescent , Adult , Aged , Calcium/analysis , Calcium-Binding Proteins/analysis , Carbonic Anhydrases/analysis , Case-Control Studies , Cross-Sectional Studies , Dental Enamel/chemistry , Durapatite/chemistry , Feeding Behavior , Female , Humans , Male , Middle Aged , Mucin-5B/analysis , Phosphorus/analysis , Saliva/metabolism , Salivary Proteins and Peptides/analysis , Secretory Rate/physiology , Young AdultABSTRACT
BACKGROUND: The American Society of Peritoneal Surface Malignancies (ASPSM) is a consortium of cancer centers performing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). This is a position paper from the ASPSM on the standardization of the delivery of HIPEC. METHODS: A survey was conducted of all cancer centers performing HIPEC in the United States. We attempted to obtain consensus by the modified method of Delphi on seven key HIPEC parameters: (1) method, (2) inflow temperature, (3) perfusate volume, (4) drug, (5) dosage, (6) timing of drug delivery, and (7) total perfusion time. Statistical analysis was performed using nonparametric tests. RESULTS: Response rates for ASPSM members (n = 45) and non-ASPSM members (n = 24) were 89 and 33 %, respectively. Of the responders from ASPSM members, 95 % agreed with implementing the proposal. Majority of the surgical oncologists favored the closed method of delivery with a standardized dual dose of mitomycin for a 90-min chemoperfusion for patients undergoing cytoreductive surgery for peritoneal carcinomatosis of colorectal origin. CONCLUSIONS: This recommendation on a standardized delivery of HIPEC in patients with colorectal cancer represents an important first step in enhancing research in this field. Studies directed at maximizing the efficacy of each of the seven key elements will need to follow.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/therapy , Consensus , Hyperthermia, Induced , Peritoneal Neoplasms/therapy , Practice Guidelines as Topic/standards , Chemotherapy, Cancer, Regional Perfusion , Combined Modality Therapy , Humans , Societies, ScientificABSTRACT
OBJECTIVES: To investigate how nutritional advice and denture adhesives may be associated with eating healthier foods. METHODS: 35 edentulous subjects (13 males and 22 females, mean age 73.9 years (55-84 years)), wearing complete dentures more than one year old, completed validated questionnaires analysing saturated fat, protein, Vitamin C, the number of servings of fruit/vegetables. In addition subjects completed the NDNS and OHIP Edent questionnaires. At baseline, nutritional information and the use of denture adhesive was provided. Subjects returned after 30 consecutive days and the questionnaires were repeated. A Wilcoxon signed rank test was used to test the effect of the denture adhesive on diet and on quality of life measures. RESULTS: The subjects increased mean intake from 2.2 portions of fruit/vegetables a day to 3.6. Fat and saturated fats were reduced from 23.2g to 11.3g and Vitamin C intake increased by 34.4mg. All were statistically significant (p<0.0001). There was a statistically significant improvement over the 30-day treatment period in subjects' ability as measured by using OHIP Edent scores to bite (p=0.017) and chew a range of foods (p=0.007). CONCLUSION: Within the confines of the study, use of simple dietary advice and denture adhesives improved diet. CLINICAL SIGNIFICANCE: The results of this pilot study suggest that denture fixatives may improve dietary behaviour of complete denture wearers.
Subject(s)
Adhesives/therapeutic use , Counseling , Denture Retention , Denture, Complete , Diet , Aged , Aged, 80 and over , Ascorbic Acid/administration & dosage , Bite Force , Dietary Fats/administration & dosage , Dietary Proteins/administration & dosage , Fatty Acids/administration & dosage , Female , Follow-Up Studies , Fruit , Humans , Male , Mastication/physiology , Middle Aged , Nutrition Policy , Nutritional Physiological Phenomena , Quality of Life , VegetablesABSTRACT
Frailty is a multidimensional geriatric syndrome characterised by a state of increased vulnerability to disease. Its causes are unclear, limiting opportunities for intervention. Age-related changes to the immune-endocrine axis are implicated. This study investigated the associations between the immune-endocrine axis and frailty as well as mortality 10 years later among men and women aged 65 to 70 years. We studied 254 participants of the Hertfordshire Ageing Study at baseline and 10-year follow-up. At baseline, they completed a health questionnaire and had collection of blood samples for immune-endocrine analysis. At follow-up, Fried frailty was characterised and mortality ascertained. Higher baseline levels of differential white cell counts (WCC), lower levels of dehydroepiandosterone sulphate (DHEAS) and higher cortisol:DHEAS ratio were all significantly associated with increased odds of frailty at 10-year follow-up. Baseline WCC and cortisol:DHEAS clearly discriminated between individuals who went on to be frail at follow-up. We present the first evidence that immune-endocrine biomarkers are associated with the likelihood of frailty as well as mortality over a 10-year period. This augments our understanding of the aetiology of frailty, and suggests that a screening programme at ages 60-70 years could help to identify individuals who are at high risk of becoming frail and who would benefit from early, targeted intervention, for example with DHEA supplementation or anti-inflammatory strategies. Progress towards the prevention of frailty would bring major health and socio-economic benefits at the individual and the population level.
Subject(s)
Aging/metabolism , Biomarkers/blood , Endocrine System/physiology , Frail Elderly , Geriatric Assessment/methods , Health Status , Immune System/physiology , Aged , Female , Follow-Up Studies , Humans , Longevity , Male , Retrospective Studies , Surveys and Questionnaires , Survival Rate/trends , Time Factors , United Kingdom/epidemiologyABSTRACT
The Health Protection Agency is changing from using detectors made from 7LiF:Mg,Ti in its photon/electron personal dosemeters, to 7LiF:Mg,Cu,P. Specifically, the Harshaw TLD-700H card is to be adopted. As a consequence of this change, the dosemeter holder is also being modified not only to accommodate the shape of the new card, but also to optimize the photon and electron response characteristics of the device. This redesign process was achieved using MCNP-4C2 and the kerma approximation, electron range/energy tables with additional electron transport calculations, and experimental validation, with different potential filters compared; the optimum filter studied was a polytetrafluoroethylene disc of diameter 18 mm and thickness 4.3 mm. Calculated relative response characteristics at different angles of incidence and energies between 16 and 6174 keV are presented for this new dosemeter configuration and compared with measured type-test results. A new estimate for the energy-dependent relative light conversion efficiency appropriate to the 7LiF:Mg,Cu,P was also derived for determining the correct dosemeter response.
Subject(s)
Thermoluminescent Dosimetry/instrumentation , Copper/chemistry , Equipment Design , Fluorides/chemistry , Lithium Compounds/chemistry , Magnesium/chemistry , Monte Carlo Method , Phosphorus/chemistry , Polytetrafluoroethylene/chemistryABSTRACT
OBJECTIVE: Sodium hexametaphosphate (SHMP) is a widely used industrial preservative commonly found in children's drinks. In this paper we examined the effect of SHMP incorporated into children's drinks on acid production by the oral biofilm by monitoring salivary concentrations of lactic acid. MATERIALS AND METHOD: Twelve healthy adult subjects with an average age 36 years (range 26-54 years) consumed 10 ml from four children's beverages (Coca Cola and three types of Sunny Delight supplemented with SHMP) and a standard solution of sucrose. Saliva was collected at intervals following exposure of the oral biofilm to the drinks and the clearance of carbohydrates and the appearance of lactate was measured using standard enzymatic techniques. RESULTS: All the carbohydrates derived from the drinks were cleared from saliva within 15 min of consumption. Comparison of two drinks [Sunny D Normal and Sunny C] with the same carbohydrate, but different SHMP concentrations suggested that SHMP in these beverages had no significant effect on acid production. CONCLUSIONS: In this clinical study the role of SHMP, incorporated in common beverages, did not inhibit acid production from carbohydrates.
Subject(s)
Biofilms/drug effects , Food Preservatives/pharmacology , Mouth/microbiology , Phosphates/pharmacology , Acids/metabolism , Adult , Beverages , Carbonated Beverages , Dietary Carbohydrates/metabolism , Dietary Sucrose/metabolism , Female , Fructose/analysis , Glucose/analysis , Humans , Lactic Acid/analysis , Male , Middle Aged , Saliva/chemistry , Sucrose/analysis , Time FactorsABSTRACT
Although clinical syndromes of visual-spatial neglect have been well described in adults, clinical features of neglect associated with subcortical dysfunction are infrequently reported in children and have not been described in detail. Unilateral visual-spatial neglect in a 7-year-old male following removal of a right subcortical juvenile pilocytic astrocytoma is reported. Preoperative baseline neurocognitive assessment of the patient established intact attentional and intellectual functioning. Postoperatively visual-spatial neglect was observed that was not accounted for by the patient's visual field deficit. Consistent with classic features of attentional neglect, increases in attentional demands led to greater errors in performance. The risk of unilateral neglect following resection of subcortical tumors that abut the thalamus or disrupt thalamo-cortical projections was confirmed in a retrospective analysis of patients referred for neurocognitive testing at our site. It was concluded that the ventral thalamus may play a role in visual-spatial attention early in development.
Subject(s)
Astrocytoma/surgery , Brain Neoplasms/surgery , Neurosurgical Procedures/adverse effects , Perceptual Disorders/diagnosis , Perceptual Disorders/etiology , Astrocytoma/diagnosis , Astrocytoma/pathology , Attention , Brain Neoplasms/diagnosis , Brain Neoplasms/pathology , Child , Functional Laterality , Hemianopsia/etiology , Humans , Intelligence Tests , Magnetic Resonance Imaging , Male , Neuropsychological Tests , Paresis/etiology , Perceptual Disorders/physiopathology , Space Perception , Stereotaxic Techniques/adverse effects , Thalamus/pathology , Thalamus/surgery , Tomography, X-Ray Computed , Visual FieldsABSTRACT
Vaccinia virus is being investigated as a replicating vector for tumor-directed gene therapy. However, the majority of cancer patients have preformed immunologic reactivity against vaccinia virus, as a result of smallpox vaccination, which may limit its use as a vector. The Yaba-like disease (YLD) virus was investigated here as an alternative, replicating poxvirus for cancer gene therapy. We have demonstrated that the YLD virus does not cross-react with vaccinia virus antibodies, and it replicates efficiently in human tumor cells. YLD virus can be expanded and purified to high titer in CV-1 cells under conditions utilized for vaccinia virus. The YLD virus RNA polymerase was able to express genes regulated by a synthetic promoter designed for use in orthopoxviruses. We sequenced the YLD virus TK gene and created a shuttle plasmid, which allowed the recombination of the green fluorescent protein (GFP) gene into the YLD virus. In a murine model of ovarian cancer, up to 38% of cells in the tumor expressed the GFP transgene 12 days after intraperitoneal virus delivery. YLD virus has favorable characteristics as a vector for cancer gene therapy, and this potential should be explored further.
Subject(s)
Genetic Therapy , Genetic Vectors , Neoplasms, Experimental/therapy , Poxviridae/genetics , Animals , Cross Reactions , Female , Mice , Mice, Nude , Poxviridae/growth & development , Poxviridae/immunology , Promoter Regions, Genetic , Vaccinia virus/genetics , Vaccinia virus/growth & development , Vaccinia virus/immunology , Virus ReplicationSubject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Chemotherapy, Cancer, Regional Perfusion/methods , Hyperthermia, Induced , Laparoscopy , Peritoneal Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/blood , Area Under Curve , Chromatography, High Pressure Liquid , Cisplatin/administration & dosage , Cisplatin/pharmacokinetics , Female , Humans , Male , Middle Aged , Mitomycin/administration & dosage , Mitomycin/pharmacokinetics , Peritoneal Neoplasms/metabolism , Prospective StudiesABSTRACT
BACKGROUND: The National Immunization Survey (NIS) and the National Health Interview Survey (NHIS) produce national coverage estimates for children aged 19 months to 35 months. The NIS is a cost-effective, random-digit-dialing telephone survey that produces national and state-level vaccination coverage estimates. The National Immunization Provider Record Check Study (NIPRCS) is conducted in conjunction with the annual NHIS, which is a face-to-face household survey. As the NIS is a telephone survey, potential coverage bias exists as the survey excludes children living in nontelephone households. METHODS: To assess the validity of estimates of vaccine coverage from the NIS, we compared 1995 and 1996 NIS national estimates with results from the NHIS/NIPRCS for the same years. RESULTS: Both the NIS and the NHIS/NIPRCS produce similar results. CONCLUSION: The NHIS/NIPRCS supports the findings of the NIS.
Subject(s)
Health Care Surveys , Immunization Programs/statistics & numerical data , Child, Preschool , Humans , Infant , National Health Programs/statistics & numerical data , Telephone , United States , Vaccination/statistics & numerical dataABSTRACT
BACKGROUND: Unresectable colorectal liver metastases are a significant clinical problem. Isolated hepatic perfusion (IHP) is a regional treatment technique that delivers high dose chemotherapy, biologic agents, and hyperthermia via a completely isolated vascular recirculating perfusion circuit as a means of regionally treating liver tumors. This study presents our results of IHP with tumor necrosis factor (TNF) plus melphalan or IHP with melphalan alone followed by infusional floxuridine (FUDR) and leucovorin in patients with advanced or refractory unresectable hepatic colorectal metastases. METHODS: Fifty-one patients with unresectable colorectal hepatic metastases underwent a 60-minute IHP with 1.5 mg/kg melphalan and hyperthermia (39 degrees C to 40 degrees C). Thirty-two patients received IHP with 1 mg TNF with melphalan and 19 patients had IHP with melphalan alone followed by monthly hepatic intra-arterial infusional (HAI) FUDR (0.2 mg/kg/day) and leucovorin (15 mg/M(2)/day) for 14 days monthly for up to 12 months. Twenty-six patients failed 1 or more previous treatment regimens for established hepatic metastases and 27 had greater than 25% hepatic replacement (PHR) by tumor. Patients were monitored for response, toxicity, and survival. RESULTS: There was 1 perioperative death (2%), and only 2 patients (4%) had measurable perfusate leak during IHP (both less than 4%). In the 32 patients treated with IHP alone there were no detectable systemic TNF or melphalan levels during perfusion. The overall objective radiographic response rate (all partial [PR]) was 76% (38 of 50 assessable patients) with a median duration of 10.5 months (range, 2 to 21 months). Twenty-four of 31 patients (77%) had a PR after IHP alone and 14 of 19 (74%) after IHP with postperfusion HAI. Median duration of response was 8.5 months after IHP alone and 14.5 months after IHP and HAI; median survival was 16 and 27 months, respectively. There were 18 PRs in 26 patients (69%) whose prior therapy had failed and 18 PRs in 27 patients (67%) with PHR of 25 or greater. CONCLUSIONS: IHP can be performed with acceptably low morbidity and has significant antitumor activity in patients with unresectable hepatic metastases from colorectal cancer including those with refractory disease or PHR of 25 or greater. HAI appears to prolong the duration of response after IHP, and this combined treatment strategy deserves additional clinical evaluation as a therapeutic modality in this setting.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Cancer, Regional Perfusion , Colorectal Neoplasms/therapy , Liver Neoplasms/secondary , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Chemotherapy, Cancer, Regional Perfusion/adverse effects , Colorectal Neoplasms/pathology , Combined Modality Therapy , Dose-Response Relationship, Drug , Female , Floxuridine/administration & dosage , Humans , Hyperthermia, Induced , Infusions, Intra-Arterial , Leucovorin/administration & dosage , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/therapy , Male , Melphalan/administration & dosage , Melphalan/blood , Middle Aged , Neoplasm Metastasis , Radiography , Survival Analysis , Tumor Necrosis Factor-alpha/administration & dosage , Tumor Necrosis Factor-alpha/analysisABSTRACT
BACKGROUND: Isolated limb perfusion (ILP) results in complete response (CR) rates of 60% to 90% in patients with regionally advanced melanoma. Survival after a CR may be influenced by various factors, particularly out-of-field disease in iliac lymph nodes (ILN) identified during lower-extremity ILP. We examined clinical and pathological parameters, including ILN status and outcome, for patients with in-transit melanoma who had a CR to ILP. METHODS: From May 1992 to July 1997, 50 patients (16 men and 34 women; median age, 57 years) with stage IIIA or IIIAB melanoma had a CR to a 90-minute hyperthermic iliac ILP with melphalan (10 mg/L limb volume, n = 20) or melphalan and tumor necrosis factor (4-6 mg+/-200 microg interferon; n = 30). Clinical and pathological parameters were analyzed by univariate and Cox proportional hazards models to determine which were associated with survival or in-field recurrence. RESULTS: The median in-field recurrence-free survival in the cohort of 50 patients after a CR to ILP was 1.4 years, and the actuarial 5-year in-field recurrence-free survival was 30%. By univariate analysis, there was a trend for improved outcome with female sex and stage IIIA (vs. IIIAB) at initial diagnosis was associated with improved survival after a CR to ILP (P = .056 and .012, respectively). Eleven (22%) of 50 patients had positive ILNs identified and resected at ILP. The probability of overall in-field recurrence was 70% after 4 years, and there was no difference between those with or without positive ILNs; median time to in-field recurrence was 13 and 19 months, respectively (P = .62). Similarly, overall survival was not influenced by positive ILN status (median [months]: +ILN, 69 vs. -ILN, 58; P = .68). Of note, Cox models identified that the risk of death was significantly greater in those with a history of prior systemic therapy (hazard ratio: 2.67 [95% confidence interval, 1.17-6.11]; P = .02) and those with an in-transit lesion size > or =1.4 cm2 (hazard ratio, 3.12 [95% confidence interval, 1.30-7.5]; P = .011). When these two variables were combined, there was a highly significant association with shortened survival (P = .002 by log-rank test). CONCLUSIONS: These data indicate that for patients undergoing ILP and in whom positive ILNs are found and resected, ILP is justified. In addition, patients who have a CR after ILP and have a history of prior treatment or larger lesions should be considered for adjuvant systemic therapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Melanoma/drug therapy , Skin Neoplasms/drug therapy , Adult , Aged , Chemotherapy, Cancer, Regional Perfusion/methods , Disease-Free Survival , Extremities/blood supply , Female , Humans , Hyperthermia, Induced/methods , Interferons/administration & dosage , Lymphatic Metastasis , Male , Melanoma/mortality , Melanoma/secondary , Melphalan/administration & dosage , Middle Aged , Neoplasm Staging , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Tumor Necrosis Factor-alpha/administration & dosageABSTRACT
BACKGROUND: The reported success of heterotopic parathyroid autotransplantation (HPA) in patients with primary hyperparathyroidism varies from 20% to 60%. The purpose of this study was to evaluate our results with HPA to help define its role in this patient group. METHODS: Between July 1985 and June 1998, 44 patients underwent 51 HPA procedures at our institution. Twenty to 25 fragments of parathyroid tissue measuring 1 to 3 mm3 each were placed into the forearm musculature. HPA results were scored as nonfunctional (requiring calcium and vitamin D), partially functional (normocalcemia on calcium alone), fully functional (normocalcemia without supplementation), or hyperfunctional (hypercalcemia without supplementation). RESULTS: Follow-up data were available for 39 patients who underwent 46 autografts (20 immediate and 26 cryopreserved). With a median follow-up of 35 months, 19 autografts (41%) were nonfunctional; 9 autografts (20%) were partially functional; 15 autografts (33%) were fully functional, and 3 autografts (7%) were hyperfunctional. Full function was observed in 35% of immediate and 31% of delayed autografts. CONCLUSIONS: One third of parathyroid autografts develop full function, and an additional one fifth develop partial function. Recurrent hyperparathyroidism is uncommon. No benefit was observed from immediate versus delayed HPA, and the modest success rate of HPA suggests that improvements in technique are warranted.
Subject(s)
Hyperparathyroidism/surgery , Parathyroid Glands/transplantation , Parathyroidectomy , Adenoma/surgery , Adult , Aged , Calcium/blood , Female , Forearm , Graft Survival , Humans , Male , Middle Aged , Multiple Endocrine Neoplasia Type 1/surgery , Parathyroid Hormone/blood , Parathyroid Neoplasms/surgery , Retrospective Studies , Transplantation, Autologous , Transplantation, Heterotopic , Treatment OutcomeABSTRACT
BACKGROUND: Hyperthermic isolated hepatic perfusion (IHP) has been shown to cause significant regression of advanced unresectable liver metastases in patients. Although there are different agents and treatment modalities used in IHP, the contribution of perfusion hyperthermia is unknown. PURPOSE: A large animal model of unresectable liver metastases and a technical standard for IHP in this model were established. This model was used to assess the effects of hyperthermia on vascular permeability of tumors and normal liver tissue during IHP. METHODS: Sixty-five New Zealand White rabbits were used in a series of experiments. Disseminated liver tumors were established by direct injection of 1 x 10(6) VX-2 cells into the portal vein by laparotomy in anesthetized animals. Several surgical perfusion techniques were explored to determine a reliable and reproducible IHP model. Vascular permeability in tumor versus liver was then assessed with Evan's Blue labeled bovine albumin under normothermic (tissue temperature 36.5 degrees C +/- 0.5 degree C), moderate hyperthermic (39 degrees C +/- 0.5 degree C), or severe hyperthermic (41 degrees C +/- 0.5 degree C) conditions. RESULTS: Tumor model and perfusion techniques were successfully established with inflow through the portal vein and outflow through an isolated segment of the inferior vena cava. A gravity driven perfusion circuit with stable perfusion parameters and complete vascular isolation was used. Vascular permeability was higher in tumor than in normal tissues (P = .03) at all time points during IHP. Hyperthermia resulted in a significant (up to 5-fold) increase in permeability of neovasculature; when severe hyperthermia was used, tumor vascular permeability was increased even more than normal liver permeability (P = .01). CONCLUSIONS: The VX-2/New Zealand White rabbit system can be used as a reproducible large-animal model for IHP of unresectable liver metastases. It can be used to characterize the contribution and mechanism of action of different treatment parameters used in IHP. Hyperthermia preferentially increases vascular permeability in tumors compared with liver tissue in a dose-dependent fashion, thus providing a mechanism for its presumed benefit during isolated organ perfusion.
Subject(s)
Capillary Permeability , Hyperthermia, Induced , Liver Circulation , Liver Neoplasms, Experimental/blood supply , Liver Neoplasms, Experimental/secondary , Neovascularization, Pathologic/metabolism , Animals , Blood Vessels/metabolism , Cattle/blood , Female , Hyperthermia, Induced/methods , Perfusion , Rabbits , Reference ValuesABSTRACT
BACKGROUND: Isolated organ perfusion with hyperthermia and melphalan with or without tumor necrosis factor-alpha has been effectively used to treat regionally confined, unresectable malignancies of both the limb and liver. Many patients, however, will eventually relapse at distant sites. We used reverse transcription-polymerase chain reaction (RT-PCR) to determine whether significant tumor microembolization occurs in patients undergoing isolated limb perfusion (ILP), isolated hepatic perfusion (IHP), or hepatic resection. METHODS: Primers specific for the human tyrosinase gene or carcinoembryonic antigen gene were designed for RT-PCR to screen melanoma or colon adenocarcinoma, respectively. RNA from human melanoma lines (Pmel and 1286) and human colon adenocarcinoma lines (H508 and HT29) were used to generate positive control cDNA. Normal human blood was inoculated with tumor cells at concentrations that ranged from 10(-2) to 10(5) tumor cells/ml of blood to define the sensitivity. Systemic and perfusate blood samples were drawn from 15 patients (8 patients underwent IHP, 5 patients underwent ILP, and 2 patients underwent resection) before the start of the operation, immediately before and during the perfusion, and postoperatively. Mononuclear cell fractions were separated from the blood samples and RNA was extracted for the RT-PCR assay. Standard primers for human beta-actin were used to confirm that cDNA was generated after the RT reaction. RESULTS: RT-PCR assay sensitivity was determined to be 10 tumor cells/ml of whole blood. Of the 8 IHP patients, 6 had colon metastases and 2 had ocular melanoma metastases to the liver. All 5 ILP patients had in transit melanoma of the extremity. Two patients with colon metastases to the liver were found to have resectable disease. There were no detectable circulating tumor cells in the systemic circulation either preoperatively or postoperatively in all 15 patients that were screened. CONCLUSIONS: RT-PCR is a highly sensitive method of detecting tumor cells in perfusate or blood. Manipulation of the limb or liver followed by resection or isolated hyperthermic perfusion does not cause detectable release of circulating tumor cells. The late development of distant metastases observed in many of these patients does not correlate with the ability to measure circulating tumor cells during regional therapy.
Subject(s)
Adenocarcinoma/drug therapy , Chemotherapy, Cancer, Regional Perfusion/adverse effects , Colonic Neoplasms/pathology , DNA, Neoplasm/analysis , Liver Neoplasms/drug therapy , Neoplastic Cells, Circulating/pathology , Adenocarcinoma/secondary , Amino Acid Sequence , Antineoplastic Agents, Alkylating/administration & dosage , Extremities , Humans , Hyperthermia, Induced , Liver Neoplasms/secondary , Melanoma/pathology , Melphalan/administration & dosage , Molecular Sequence Data , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
The pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) was characterized in patients with peritoneal carcinomatosis. Cisplatin was added into the perfusate with escalating doses from 100 mg/m2 to 400 mg/m2. The hyperthermic perfusion was maintained for 90 minutes with a flow rate of 1.5 L/min and a target peritoneal temperature of 42.5 degrees C after a tumor debulking procedure. Samples of both the perfusate and blood were obtained during the perfusion and 30 minutes after the perfusion. Cisplatin plasma and perfusate concentrations were determined by flameless atomic absorption spectrometry with a lower limit of detection of 2 ng/ml and a coefficient of variation (CV) < 10%. Fifty-six patients were enrolled in the study. The mean (+/- SD) percentage of cisplatin present in the perfusate at the completion of perfusion was 27.8% +/- 20% of the total dose. The maximum cisplatin concentrations in the perfusate were 10 times higher than those in plasma. The area under the concentration-time curve (AUC) of the perfusate was 13 times higher than the AUC of plasma. A two-compartment model with an additional peritoneal cavity compartment fits to the data best based on the Akaike information criterion. However, the interpatient variability was considerably high (CV < 100%). In conclusion, cisplatin administered by hyperthermic peritoneal perfusion resulted in a pharmacological advantage by obtaining higher and direct drug exposure to the tumor in the peritoneal cavity while limiting systemic absorption and toxicity. Using a complex two-compartment model, the authors were able to characterize the pharmacokinetics of cisplatin given intraperitoneally via this technique.
Subject(s)
Antineoplastic Agents/pharmacokinetics , Cisplatin/pharmacokinetics , Hyperthermia, Induced , Peritoneal Neoplasms/therapy , Adult , Aged , Area Under Curve , Chemotherapy, Cancer, Regional Perfusion , Cisplatin/blood , Humans , Middle AgedABSTRACT
Every seven seconds, a baby boomer turns 50. These 77 million aging revolutionaries will transform health care with their nontraditional expectations and their willingness to "vote" with their discretionary dollars. Toss in the increasing popularity of alternative medicine and the trend toward direct commerce between consumers and providers, and you have the recipe for what health care will look like in the 21st century. It will be unlike anything seen before.